KRAS and squamous cell lung carcinoma: EGFR and KRAS mutations were low in lung squamous cell carcinomas, and had no significant correlation with clinical features.Before using tyrosine kinase inhibitor targeted therapy, EGFR and KRAS mutations should be detected in patients with lung squamous cell carcinomas.